Market closed
PROCEPT BioRobotics/$PRCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Ticker
$PRCT
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
756
Website
PRCT Metrics
BasicAdvanced
$3.2B
-
-$1.75
1.05
-
Price and volume
Market cap
$3.2B
Beta
1.05
52-week high
$96.70
52-week low
$45.56
Average daily volume
972K
Financial strength
Current ratio
9.069
Quick ratio
7.852
Long term debt to equity
19.477
Total debt to equity
20.449
Interest coverage (TTM)
-23.09%
Management effectiveness
Return on assets (TTM)
-12.86%
Return on equity (TTM)
-26.77%
Valuation
Price to revenue (TTM)
13.372
Price to book
7.83
Price to tangible book (TTM)
7.85
Price to free cash flow (TTM)
-28.97
Growth
Revenue change (TTM)
64.84%
Earnings per share change (TTM)
-21.74%
3-year revenue growth (CAGR)
86.74%
3-year earnings per share growth (CAGR)
-21.55%
What the Analysts think about PRCT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
PRCT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PRCT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PRCT News
AllArticlesVideos
Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
Seeking Alpha·20 hours ago
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
GlobeNewsWire·2 weeks ago
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for PROCEPT BioRobotics stock?
PROCEPT BioRobotics (PRCT) has a market cap of $3.2B as of March 12, 2025.
What is the P/E ratio for PROCEPT BioRobotics stock?
The price to earnings (P/E) ratio for PROCEPT BioRobotics (PRCT) stock is 0 as of March 12, 2025.
Does PROCEPT BioRobotics stock pay dividends?
No, PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next PROCEPT BioRobotics dividend payment date?
PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.